icon
icon
icon
icon
Upgrade
icon

The new drug of Viking (VKTX.US), a "new star" in the weight loss drug industry, has entered the late stage of R&D, and the share price of "NuoLi" fell sharply.

AInvestThursday, Jul 25, 2024 8:10 am ET
1min read

We learned from Zhitong Finance that the shares of "obesity drug giants" Lilly(LLY.US) and Novo Nordisk(NVO.US) fell more than 2% in pre-market trading on Thursday, after Viking Therapeutics(VKTX.US) announced plans to start its late-stage trial of its obesity candidate drug VK2735 later this year. Viking announced its 2024 second-quarter earnings on Wednesday, beating expectations and pushing its shares up nearly 17% in pre-market trading on Thursday. Viking's plans for VK2735 suggest an accelerated timeline for its development.

Viking's plans for VK2735 suggest an accelerated timeline for its development. The biotech company previously said it would begin a Phase 2 trial of the candidate drug after obtaining positive data in a mid-stage trial. "We are moving forward to bring this compound into Phase 3 development, and we are currently preparing for the second phase end meeting with the agency, and we expect that to be later this year," said Brian Lian, the company's chief executive, after receiving written feedback from the FDA.

Meanwhile, the diabetes and obesity treatment market is competitive. Eli Lilly(PFE.US), Amgen(AMGN.US), Altimmune(ALT.US) and Sugden Biological(GPCR.US) are also vying for a piece of the lucrative obesity drug market, all seeking to develop new drugs. AstraZeneca(AZN.US) has also bet on the GLP-1 drug development pipeline, signing an exclusive license agreement with local biotech company Chinoy Biopharma for ECC5004 in 2023, worth $2 billion. Roche bought obesity drug developer Carmot Therapeutics for $2.7 billion this year, entering the obesity treatment market. But these companies were largely unaffected by the news, with their shares trading flat in pre-market trading.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.